Treatment of mastitis and applicator therefor

Abstract: A method for treating mastitis which comprises the use of an infusion of an effective amount of (mon)oxychlorosene or sodium oxychlorosene in an aqueous carrier is disclosed. A mastitis treatment infusion applicator which comprises a body portion (1) including a compartment (2) containing a first material which is an aqueous carrier, a cap portion (3) including a compartment (4) containing a second material which is (mon)oxychlorosene or sodium oxychlorosene, a seal (5) arranged on either the body or cap portion to separate the two compartments, and seal-­ breaking means (6) arranged on either the cap or body portion respectively, wherein the cap and body portion are movable relative to one another between a first position in which the seal is intact and a second position in which the seal is broken and in which the materials in the two compartments may come into contact, at least the surfaces contacting the second material being fluorinated is also disclosed.

Description: This invention relates to the treatment of mastitis; more particularly, it relates to the treatment of bovine mastitis, which may include so called "sub-clinical mastitis" and "summer mastitis". Specifically, the present invention provides the use of (mon)oxychlorosene or sodium oxychlorosene for the manufacture of a medicament for the treatment of mastitis. Although in general terms the present invention may be applied to all animals suffering from mastitis conditions, it will be largely illustrated with particular reference to dairy cattle. In short, mastitis is a condition caused by bacterial invasion of the milking organs resulting inter alia in painful inflammation and unwanted secretion. Numerous microorganisms are thought to contribute to the problem, but a handful of causative organisms are most common and hence serious, e.g. Staph. coagulase positive , Str. dysgalactiae , uberis and agalactiae and E. coli . "Summer mastitis" is commonly vectored by flies in nonlactating animals. In "sub-clinical" cases, animals suffer from the condition and may act as a source of infection, but do not manifest the full symptoms. For many years, mastitis in dairy cattle has been treated by infusing comparatively small quantities of antibiotic suspensions into the udder after voiding as far as possible. Numerous such materials have been used and all involve several problems for the farmer/producer and the user/consumer. As current antibiotics are long-acting after a course of treatment, the milking udder continues to excrete antibiotic-containing milk. The levels diminish with time, but remain problematic generally for between 6 and 10 milkings. During this period, the milk contains sufficient antibiotic active to inhibit significantly the growth of organisms in the milk, in particular those required for processing the milk into yoghurt or cheese, and also to have marked effects on the intestinal flora of consumers, particularly young children with high milk intake and low body weight. Also, it is generally recognized that a proportion of the population have allergic reactions to some antibiotics, particularly penicillins. For such reasons, in countries with legislation effectively controlling the sales of antibiotics, there are prescribed acceptable levels of antibiotic residues. Generally, the movement of such maxima is downwards and hence the period for which an animal's milk must be withheld from supply (i.e. discarded) is increasing. The use of prophylactic chlorine teat dips is also known. It has now been found that (mon)oxychlorosene or sodium oxychlorosene in an aqueous medium is an effective treatment for mastitis in a lactating or nonlactating dairy animal. Such does not preclude other treatments and may indeed cooperate therewith. The active ingredient is known for use in human medicine as a disinfectant, but has never been suggested for veterinary use, specifically for the treatment of mastitis by infusion. As indicated above, the present invention provides the use of (mon)oxychlorosene or sodium oxychlorosene for the manufacture of a medicament for treatment of mastitis. In general terms, the treatment for mastitis comprises the use of an infusion of an effective amount of (mon)oxychlorosene or sodium oxychlorosene in an aqueous carrier. The compositions comprise the above active ingredient in an aqueous medium, which may be water or, preferably, saline solution. It is important that the infusion be prepared at the time of use. According to Martindale, The Extra Pharmacopoeia, (mon)oxychlorosene is the hypochlorous acid complex of a mixture of the phenyl sulphonate derivatives of aliphatic hydrocarbons. It is a fine white powder, which dissolves slowly in water and then hydrolyses rapidly. It is currently commercially available as "Clorpactin®" (Registered Trade Mark). Aqueous solutions of sodium (mon)oxychlorosene, in particular in physiological saline, prepared at the point of use, and infused into an infected cow's quarter udder have now been shown to be efficacious in treating mastitis. Generally, a course of 3 or 4 infusions is sufficient to alleviate the clinical symptoms of the condition. This is comparable with conventional antibiotic treatment. The active ingredient is thought to react in the infused quarter by releasing hypochlorous acid gas into the udder cavity and hence killing invading organisms. It is relatively short, but very strong acting. The active ingredient hence degrades during the reaction leaving a small amount of residue in the milk and subsequently extracted from the treated quarter(s), but such residue is non-inhibitory to all currently recognized tests for inhibitory substances. In particular, it will not affect cheese and yoghurt starter cultures and is of proven low toxicity. For such reasons, it is possible to use the milk with only one milking needing to be discarded after a course of treatment. Unlike treatment with antibiotics which may be systematically absorbed, the new approach allows nonaffected quarters to be milked normally during a course of treatment. Also, while some bacteria may prove antibiotic resistant, the same cannot be said in relation to the presently-produced medicament. The present use utilizes dilute aqueous solutions of the active ingredient, for example up to 2.5% w/v. Commonly, a course of treatment would involve the use of, say, from 4 to 6 infusions of 40 ml aliquots of 1.25% w/v solutions. Normally, a course of treatment would coincide with the milking schedule over several days, but if desired the voiding/infusing might be repeated, say, hourly, so that an animal could be back "on-line" the next day, for example. Moreover, bearing in mind the problem of sub-clinical mastitis, periodic preventative treatments might be considered as minimal disruption would be involved. Conventionally, an infusion of freshly-prepared material would be given using a syringe. For the present use, a mastitis treatment infusion applicator is preferably used, which is provided charged in separate compartments with the active ingredient and the vehicle, mixing being accomplished when required. (See EP-A-323109 for further details.) The following illustrates the present invention: The LD50 value of sterilized, γ-irradiated (25 kGy, 2.5 megarads) "Clorpactin® WCS-90" (sodium oxychlorosene) in a milk vehicle was found to be in excess of 5.00 g/kg by the oral route on rats. In further safety studies, the tolerance of dairy cattle has been investigated: Sixty one animals have been subjected to courses of six infusions at 2.5% w/v sodium oxychlorosene (double normal strength). No adverse effects were found. Studies have also been carried out on twelve infusions of 1.25% w/v sodium oxychlorosene at consecutive milkings (double normal length of course of treatment) and six infusions of 1.25% w/v sodium oxychlorosene using 80 ml (double normal volume). No adverse effects were found. There is now reported a residue study using full normal courses of treatment (1.25% w/v sodium oxychlorosene). The purpose of this investigation is to monitor the levels of residual "Clorpactin® WCS-90" detectable in milk during a course of treatment. The completed work, which takes the form of a series of individual studies, monitors the level of residues in milk from cows that were subjected to six infusions of a single normal strength "Clorpactin®" dose during infusion and for a series of milkings after the treatment was complete. Analysis of the milk samples from each cow was by ion-pair reverse-phase chromatography. Calculation of the "Clorpactin®" residues was, in the case of Study 01, by the peak height method, as the milk used for the standards was obtained from a different source from the cows under test (consequent detection limit 7 ppm). In studies, 02, 03 and 04 as the standards were made in milk obtained from the cow under test a few days prior to treatment, the peak area method was used (detection limit 1 ppm). Study 04, on mastitic cows was again by the peak area method with the standards being made up in milk obtained several days after treatment had finished. Treatments: Study 01 Two mid-lactation cows (Fresian) were selected for the trial, with each being subjected to one course of treatment with the "Clorpactin® WCS-90". Treatments comprised six infusions following six successive milkings, of "Clorpactin®" at a single normal strength dose (0.5 g per 40 ml of physiological saline) Study 02 Two healthy mid-lactation cows (Fresian) were selected for this trial, with again each cow being subjected to a single course of treatment with "Clorpactin® WCS-90". Study 02 differed from Study 01 in that a sample of the milk from the quarters under test was removed from the cow a few days prior to treatment, to enable accurate standards to be prepared. Study 03 Three healthy mid-lactation cows (Fresian) were selected for the trial, with each being subjected to one course of treatment with the "Clorpactin® WCS-90", to each of the four quarters of the animals. The milk from all four quarters was monitored for residues during and after treatment, with the standards being made up in milk obtained from the quarters a few days before the trial. Study 04 Two mastitic cows, used in the efficacy study, were monitored for residues in the milk from a point where the milk appeared to be normal. It was not possible to evaluate the severely mastitic milk as no standards may be prepared to evaluate milk that is constantly changing in composition. The standards used in this case were made in milk obtained some 4 days after the last sample was taken. The results from these studies are detailed in the following Table and are largely self-explanatory. The first infusion occurred after milking 1, with the consequence that milking 1 represents the background. Means cited at the foot of the Table are calculated taking the <7 ppm and <1 ppm results as 7 and 1, respectively. In the majority of cases, the background has been achieved by the 8th milking (one milking after treatment was completed). First infusion carried out after milking number 1 on this Table. The mean of results from samples taken after the one milking withdrawal period is 3.1 ppm. 10 x 3.1 - 31 ppm is far less than the minimum inhibitory concentration which is approximately 2000 ppm against E . coli and St . faecalis (intestinal flora). A definition of nil effect level is greater than 2800 ppm. This is more than 600 times the mean level found. These calculations support a one milking withdrawal period. The conclusion from this series of experimental studies is that while the results obtained from the milk samples taken during treatment are variable, the levels of "Clorpactin®" detected after treatment is complete quickly drops off to background. The data obtained, therefore, strongly supports a one milking withdrawal after treatment. The inhibitory effect of "Clorpactin®" on starter cultures was also investigated: Raw whole milk was pasteurized and spiked with various concentrations of freshly prepared "Clorpactin®". These samples were inoculated with the starters Streptococcus thermophilus and Lactobacillus bulgarius contained in natural yoghurt, incubated at 37°/5 hours and the percent lactic acid determined by titratable acidity (BSI, 1741:1963). Levels of up to 0.01% (100 ppm) "Clorpactin®" had no effect on lactic acid production with starters in both the control and "Clorpactin®"-spiked milks producing about 0.9% lactic acid. This is within the recommended level of 0.90-0.95% acidity. The mother culture of natural yoghurt had an acidity of 1.28% lactic acid which is rather high. In conclusion, "Clorpactin®" had no adverse affect on yoghurt starter culture activity, which is normally very sensitive to inhibitors. An experimental study was conducted to determine if any absorption occurs between quarters during a course of treatment with "Clorpactin® WCS-90". The method used was to infuse two of the quarters of a healthy cow with a double normal strength course of treatment and to monitor each of the four quarters for "Clorpactin®" residues, both during and after the trial. This with the assumption that if the material were being transferred between quarters by any mechanism it would be detected in the untreated quarters. Analysis of the milk samples from each quarter was by ion-pair reverse-phase chromatography. Calculation of the "Clorpactin®" residues was by peak area with the milk used for the standards being prepared from milk obtained several days before treatment. Separate sets of standards were prepared for each quarter with the analysis being conducted "blind" i.e. the investigator was not informed beforehand which samples had been obtained from quarters which had been infused with "Clorpactin" during the course of treatments. A single mid-lactation cow (Fresian) was selected for the trial. Two of the quarters were each infused with a double normal dose of "Clorpactin® WCS-90" (2 x 0.5 g in 40 ml of physiological saline) on six consecutive occasions following 6 milkings. The milk from all four quarters was monitored for residues both during and after the trial to determine if any transfer to untreated quarters had occurred. The results from this study are presented in the following Table. The first infusion occurred after Milking No. 1, with the consequence that Milking 1 represents the background. As may be seen, the level returns quickly to background after treatment is complete and is clear by Milking No. 8. No evidence of any "Clorpactin" was detected in the untreated quarters. The conclusion to be drawn is that, even with a double normal strength infusion, there is no mechanism of transference of "Clorpactin®" to the untreated quarters, either during or after treatment. The evidence of this study suggests that only milk from the treated quarter need be discarded, and that milk from the untreated quarters may at all times be added to the bulk tank supply. In addition to the above safety aspects, the efficacy of the presently-produced medicament was also investigated. Efficacy studies used half herds on a positive control and half herds on the experimental treatment. The protocol agreed was that herds were randomly split into two halves by number. Odd numbered cows received experimental treatment and even numbered cows received the positive control. Any animal sufficiently badly affected (i.e. systematically affected) should be the subject of a visit from a veterinary surgeon and was not included in the trial on either side. Clinical symptoms were noted for each case at each milking and records were kept of each case. Milk samples of each infected quarter were sent to the MMB Laboratories for cell count and bacterial identification as follows:. 1. Initial (No treatment) 2. 24 hrs (before 2nd treatment) 3. 48 hrs (before 4th treatment) 4. 72 hrs (before 6th treatment) 5. 96 hrs (24 hrs post treatment) 6. 120 hrs (48 hrs post treatment) 7. 1 week (9 days post treatment) 8. 2 weeks (16 days post treatment) A clinical cure is defined as the udder returning to normal function. Experimental treatment: 40 ml of 1.25% w/v solution of sodium oxychlorosene infused 6 times at 6 milkings. Positive control: 1 full tube of 100 mg procaine penicillin/100 mg dihydro-streptomycin sulphate infused 6 times at 6 milkings. Five measurements can be made from the figures available: (a) Clinical cure rate (b) Microbiological cure rate (c) Mean cell counts (d) Mean number of tubes to effect a clinical cure (e) Mean number of tubes to effect a microbiological cure Clinical assay: Experimental Routine Odd numbered animals. Sodium oxychlorosene. 40 ml 1.25% w/v. 6 times at successive milkings. Causative Organism Total Cases of 6 Infusions Clinical Cures % Clinical Cures Staph.coagulase positive 72 65 90 E.coli 4 3 Str.dysgalactiae 10 7 70 Str.uberis 25 19 76 Str.agalactiae 51 41 82 Positive Control Even numbered animals. Procaine penicillin/Dihydrostreptomycin sulphate. 6 times at 6 milkings. Causative Organism Total Cases of 6 Infusions Clinical Cures % Clinical Cures Stanh.coagulase positive 38 26 68 E.coli 1 0 Str.dysgalactiae 1 1 Str.uberis 4 2 Str.agalactiae 3 2 Statistical treatment of the results shows that, at 95% confidence level, the present 1.25% w/v sodium oxychlorosene treatment is superior to the conventional antibiotic. Somatic cell counts in milk from individual quarters is an indication of the state of health of that quarter. The higher the cell count, the greater is the degree of infection or the irritant effect in the udder. The mean cell counts for all experimental milk samples submitted to the MMB are shown below. It is not always possible to obtain a cell count if the milk is obviously mastitic or if the sample deteriorates in transit. One problem with sodium oxychlorosene samples is that, due to lack of inhibitory effects, samples in transit may deteriorate quite rapidly. Samples containing antibiotic inhibitors are generally better protected from microbiological deterioration in transit. Some samples, when specifically needed for cell counts and not for causative organism assay, have been protected by the addition of formalin. This was carried out, for instance, when the irritancy studies were carried out. Mean Cell Counts During and After Completed Treatments Day Conventional antibiotic n Sodium oxychlorosene (1.25%) n 0 6326 27 6870 44 1 5570 24 6092 46 2 3092 23 4912 54 3 3919 21 4845 44 4 2307 18 3468 25 5 2637 14 2018 21 12 1372 22 1576 23 19 1358 20 965 21 (The variations in n, the number of determinations from which the mean cell count is calculated, are due to various factors, such as samples leaking in transit, faster decomposition of samples in hot weather, especially where no inhibitor substances are present (i.e. sodium oxychlorosene) Mean number of infusions to effect a clinical cure where a clinical cure is affected after up to 6 infusions. Experimental Mean number of infusions n = 70 Sodium oxychlorosene 1.25% w/v x = 4.11 On₁ = 1.61 Positive Control Mean number of infusions n = 30 Conventional antibiotic x = 5.13 On₁ = 1.10 Analysis Experimental vs Positive control. 72 degrees of freedom. t = 3.098. Significant (p < 0.01)

Claims: Use of (mon)oxychlorosene or sodium oxychlorosene for the manufacture of a medicament for the treatment of mastitis.

Inventors: CORBY MICHAEL PETER, CORBY, MICHAEL PETER
Applicants: DIVERSEY CORP, UNITED GUARDIAN INC, DIVERSEY CORPORATION, UNITED GUARDIAN, INC.
Application year: 1988
Main classification: A61K31
IPC codes: A61D1